Exports from Ranbaxy plants at Toansa and Dewas to Europe will remain suspended as probes are continuing, even as Indian authorities have withdrawn the certification of manufacturing standards from one of the units, European health regulator EMA said on Wednesday.
The European Medicines Agency (EMA) said Indian authorities had withdrawn certification to the Toansa plant, while an international inspection of the Dewas plant is been planned for June.
"EMA and national medicines authorities in the EU are progressing with their assessment of reports of non-compliance with Good Manufacturing Practice at two Ranbaxy Laboratories' sites in India," an EMA spokesperson said.
